<DOC>
	<DOC>NCT02480153</DOC>
	<brief_summary>The study will assess the efficacy, safety, and immunogenicity of PF-06410293 and adalimumab in combination with methotrexate in subjects with moderately to severly active rheumatoid arthritis who have had an inadequate response to methotrexate.</brief_summary>
	<brief_title>A Study Of PF-06410293 (Adalimumab-Pfizer) And Adalimumab (Humira) In Combination With Methotrexate In Subjects With Active Rheumatoid Arthritis (REFLECTIONS B538-02).</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Diagnosis of rheumatoid arthritis based on 2010 ACR/EULAR criteria for at least 4 months. At least 6 tender (of 68 assessed) and 6 swollen (of 66 assessed) joints at screening and baseline. HsCRP equal or greater than 8 mg/L. Must have received methotrexate for at least 12 weeks and been on a stable dose for at least 4 weeks prior to the first study dose. Evidence of untreated or inadequately treated latent or active TB. Evidence of uncontrolled, clinically significant diseases, including moderate or severe heart failure (NYHA Class III/IV) or malignancy in the previous 5 years. History of infection requiring hospitalization or parenteral antimicrobial therapy within 6 months prior to first dose of study drug. May have received no more than 2 doses of one biologic therapy (other than adalimumab or lymphocyte depleting therapy). Any second DMARD must be washed out prior to the first study dose.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Phase 3</keyword>
	<keyword>adalimumab</keyword>
	<keyword>rheumatoid arthritis</keyword>
</DOC>